Sanara MedTech Reports Strong Preliminary 2025 Results, Positive 2026 Guidance, and Secures Major Vizient Contract
SMTI is trading near its 52-week low of $18.9 (11% above the low).
Summary
Sanara MedTech Inc. announced strong preliminary financial results for Q4 and full year 2025, provided positive revenue guidance for 2026, and secured a significant Innovative Technology contract with Vizient for its BIASURGE product.
Key Events · Earnings and Guidance · SMTI
-
Preliminary 2025 Financials Reported
The company reported preliminary Q4 2025 net revenue of $27.2 million to $27.7 million, representing 11% to 13% year-over-year growth excluding a prior-year one-time sales boost. Full year 2025 net revenue is expected to be $102.7 million to $103.2 million, an increase of 21% to 22% year-over-year on an adjusted basis.
-
Introduces Positive 2026 Financial Guidance
Sanara MedTech expects full year 2026 net revenue to range from $116 million to $121 million, indicating growth of approximately 13% to 17% compared to the midpoint of 2025's expected net revenue.
-
Secures Major Innovative Technology Contract with Vizient
The BIASURGE product received an Innovative Technology contract from Vizient, Inc., the nation's largest provider-driven healthcare performance improvement company. This contract significantly expands access to BIASURGE at contracted pricing for Vizient's extensive network of healthcare facility customers, effective January 1, 2026.
-
Increased Long-Term Debt
As of December 31, 2025, the company's long-term debt increased to approximately $46.0 million, up from $30.7 million as of December 31, 2024.
Analysis · SMTI · Industrial Applications And Services
This 8-K provides a positive outlook for Sanara MedTech, driven by solid preliminary 2025 revenue growth and optimistic 2026 guidance. The most impactful news is the Innovative Technology contract with Vizient, the nation's largest group purchasing organization, which is expected to significantly boost market penetration and sales for the BIASURGE product. While long-term debt increased, the overall financial health appears stable with a slight increase in cash. Investors should view this as a strong signal for continued operational execution and revenue expansion in the surgical solutions market.
At the time of this filing, SMTI was trading at $21.00 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $198.8M. The 52-week trading range was $18.90 to $38.68. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.